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Abstract
Background
Human hookworms (Necator americanus, Ancylostoma duodenale, and Ancylostoma cey-
lanicum) are intestinal blood-feeding parasites that infect ~500 million people worldwide and
are among the leading causes of iron-deficiency anemia in the developing world. Drugs are
useful against hookworm infections, but hookworms rapidly reinfect people, and the para-
sites can develop drug resistance. Therefore, having a hookworm vaccine would be of tre-
mendous benefit.
Methodology/Principal findings
We investigated the vaccine efficacy in outbred Syrian hamsters of three A. ceylanicum
hookworm antigen candidates from two classes of proteins previously identified as promis-
ing vaccine candidates. These include two intestinally-enriched, putatively secreted cathep-
sin B cysteine proteases (AceyCP1, AceyCPL) and one small Kunitz-type protease inhibitor
(AceySKPI3). Recombinant proteins were produced in Pichia pastoris, and adsorbed to
Alhydrogel. Recombinant AceyCPL (rAceyCPL)/Alhydrogel and rAceySKPI3/Alhydrogel
induced high serum immunoglobulin G (IgG) titers in 8/8 vaccinates, but were not protective.
rAceyCP1/Alhydrogel induced intermediate serum IgG titers in ~60% of vaccinates in two
different trials. rAceyCP1 serum IgG responders had highly significantly decreased hook-
worm burdens, fecal egg counts and clinical pathology compared to Alhydrogel controls and
nonresponders. Protection was highly correlated with rAceyCP1 serum IgG titer. Antisera
from rAceyCP1 serum IgG responders, but not nonresponders or rAceyCPL/Alhydrogel
vaccinates, significantly reduced adult A. ceylanicum motility in vitro. Furthermore,
rAceyCP1 serum IgG responders had canonical Th2-specific recall responses (IL4, IL5,
IL13) in splenocytes stimulated ex vivo.
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Data Availability Statement: GenBank accession
numbers for the cloned CDSs of AceyCP1,
AceyCPL and AceySKPI3 are JARK01001490.1
(Acey_s0154.g3007.t1 CDS DNA sequence),
JARK01000132.1 (Acey_s0532.g3038.t1 CDS DNA
sequence), and JARK01001370.1 (Acey_s0034.
g2829.t1 CDS DNA sequence), respectively;
GenBank accession numbers for their amino acid
sequences are EYB96044.1 (Acey_s0154.g3007.t1
protein sequence), EYC42402.1 (Acey_s0532.
g3038.t1 protein sequence), and EYC16157.1
Conclusions/Significance
These findings indicate that rAceyCP1 is a promising vaccine candidate and validates a
genomic/transcriptomic approach to human hookworm vaccine discovery.
Author summary
Hookworms are voracious, blood-feeding, soil-transmitted nematode parasites. Adult
hookworms infect the small intestine, causing iron-deficiency anemia and other compli-
cations. Hookworms are among the most disabling parasites of the developing world.
Drugs are useful for controlling hookworm disease. However, because people often get
reinfected rapidly and parasites can develop drug resistance, a vaccine that provides long-
term protection would improve control and help lead to eradication. At present, there is
no licensed hookworm vaccine, and progress towards a vaccine has been limited. We
identified a cysteine protease in the intestine of the human hookworm Ancylostoma ceyla-
nicum that is among the most strongly expressed genes during blood feeding and that
may help digest blood and be essential for hookworm survival. Vaccination of hamsters
with this cysteine protease gave high levels of protection when antigen-specific antibodies
in the blood were induced. These antigen-specific antibodies also made hookworms less
mobile in culture. This cysteine protease is a promising candidate for further investigation
as a human hookworm vaccine antigen.
Introduction
Human hookworms (Necator americanus, Ancylostoma duodenale, and Ancylostoma ceylani-
cum) are soil-transmitted nematodes (STNs) that infect the small intestine and feed on blood
[1]. Human STNs encompass three phylogenetically distant parasites: hookworms, large
roundworms (Ascaris lumbricoides), and whipworms (Trichuris trichiura). Among human
STNs, hookworms carry the highest disease burden [2]. In children, infection by hookworms
causes significant growth stunting, cognitive deficiencies, malnutrition, iron-deficiency ane-
mia and hypoproteinemia; in adults infection results in adverse birth outcomes (e.g., low birth-
weight babies) and reduced productivity [3–5]. It is estimated that hookworms infect ~500
million people worldwide [6], and although concentrated in Latin America, sub-Saharan
Africa, and Southeast Asia, even people in impoverished regions of the United States (US) still
get infected [1,7]. Once at 40% prevalence in the southern US (circa 1911), hookworm infec-
tions led to an estimated 43% reduction in future earnings of children infected and were
responsible for 22% of the income gap and 50% of the literacy gap between North and South
[8]. The elimination of hookworms via treatment campaigns, improved sanitation, education,
and economic development undoubtedly had a major impact on the vitalization and success of
the South today. Currently, hookworm disease is estimated to cause 4.1 million disability
adjusted life years (DALYs) and US$139 billion in indirect economic losses each year [9].
Hookworms are the second most important parasitic cause of global anemia after malaria [10].
Mass drug administration (MDA) of benzimidazoles (albendazole, mebendazole) in
school-aged children is the current control measure for hookworms [11,12]. From 1990–2013,
MDA reduced hookworm prevalence by only 5.1%, compared to 25.5% reduction for A. lum-
bricoides [6]. Additionally, poor efficacy of mebendazole against hookworms is well known
[13] and poor or reduced efficacy of albendazole against hookworms is being reported in
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multiple locations around the world (e.g., egg reduction rates as low as 0% in Ghana [14] and
cure rates as low as 36% in Lao PDR [15]). Veterinary parasites phylogenetically and biologi-
cally similar to hookworms (e.g., the blood-feeding Haemonchus contortus) develop resistance
to anthelmintic drugs frequently, rapidly, and broadly [16,17]. Water, sanitation and hygiene
(WASH) is being explored as a control strategy to combine with MDA [18]. Improvements in
WASH (water, sanitation, and hygiene), although important, are insufficient to tackle the
enormous STN problem alone [18–20]. Having a vaccine to prevent infection from occurring
in the first place would be of tremendous benefit.
Although it is widely accepted that a hookworm vaccine is needed [21], there is only a single
phase 1 clinical trial underway testing two individual recombinant hookworm proteins formu-
lated on the Th2 adjuvant Alhydrogel [22]. There are no other candidates in advanced preclin-
ical development [23]. Because targeting infectious third staged larval (L3i) antigens carries
the risk of triggering allergic reactions in previously exposed people [24], efforts are focused
on adult stage antigens, namely an aspartic protease (APR1) and a glutathione S-transferase
(GST1) [25]. Both APR1 and GST1 localize to the adult canine hookworm Ancylostoma cani-
num intestine (and non-intestinal tissues); these enzymes are thought to help digest hemoglo-
bin and detoxify heme, respectively [25–28]. In canine and hamster models, recombinant
protein immunogens from A. caninum gave 33–53% decreased hookworm burdens [26,27,29].
However, in a phase 1a trial, although rNaGST1 was safe and immunogenic in human volun-
teers [30], IgG had negligible neutralizing effect on rNaGST1 enzymatic activity, despite the
observation that IgG from immunized mice were highly neutralizing [31]; these results suggest
a decreased potential for this vaccine in human trials. It remains crucial that further and
expanded efforts be undertaken to develop new hookworm vaccines. Development of hook-
worm vaccines, however, have been limited and lag far behind more concerted efforts, such as
against malaria [23,32]. This may be in part because full genomes for human hookworms were
formerly unavailable, which prevented large-scale reverse vaccinology [33] against hook-
worms. This situation has recently been addressed for all three species of human hookworms
[34–36].
Genomics and transcriptomics for A. ceylanicum hookworm infections in hamsters is being
used to identify new and potent vaccine antigen candidates [35]. Syrian hamsters are the only
laboratory rodent permissive for the human hookworm life cycle, and A. ceylanicum infections
in hamsters are an excellent model for hookworm infections in humans [37]. We previously
identified two classes of A. ceylanicum genes, that are strongly expressed and upregulated dur-
ing blood feeding, as encoding potential antigen candidates [35]: cathepsin B cysteine prote-
ases (CPs) and small Kunitz-type protease inhibitors (SKPIs). Here, we explore the vaccine
efficacy of two CPs and one SKPI (AceyCP1, AceyCPL, AceySKPI3) using the A. ceylanicum
hookworm—hamster model system, and investigate functional and immunological aspects of
protection with one of these vaccine candidates.
Methods
Ethics statement
Animal experimentation was carried out under protocols approved by the University of Mas-
sachusetts Medical School Institutional Animal Care and Use Committees (IACUC). All hous-
ing and care of laboratory animals used in this study conform to the NIH Guide for the Care
and Use of Laboratory Animals in Research and all requirements and all regulations issued by
the United States Department of Agriculture, including regulations implementing the Animal
Welfare Act (P.L. 89–544).
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Animals
Male Syrian hamsters (strain HsdHan:AURA) were purchased from Envigo at 3 weeks of age
and housed 4 hamsters per cage. Hamsters were provided with food and water ad libitum.
Male hamsters were used for all studies because female hamsters are ~5-fold less susceptible to
A. ceylanicum infection. Using females would require much larger numbers of animals to
achieve adequate infection intensity, prevalence, and statistical significance.
RNA-seq analysis
To assess intestinal versus non-intestinal gene expression for A. ceylanicum genes (including
those encoding vaccine candidates in this study), we used RNA-seq data for A. ceylanicum that
we and others had previously generated from whole worms and adult male intestine [35,38].
These data were a mixture of paired- and single-end reads with varying lengths. To make
cross-comparisons of these data as unbiased as possible, we trimmed all read sets to have sin-
gle-end 50-nt reads, using quality_trim_fastq.pl and the arguments "-q 33 -u 50". We quality-
filtered RNA-seq reads by running Trimmomatic 0.36 with the following arguments: "java -jar
$TRIM/trimmomatic-0.36.jar SE -threads 7 -phred33 [input read FASTQ file] [output read
FASTQ file] ILLUMINACLIP:[illumina adaptors sequence FASTA file]:2:30:10 LEADING:3
TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:50". The sequence file for Illumina adaptors
included both sequences and reverse-complemented sequences for all of the following Illu-
mina adaptor sequences from manufacturer’s instructions: TruSeq Universal Adapter and
TruSeq Adapter Index 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 25,
and 27. We assayed expression levels against our previously published protein-coding gene/
transcript set for A. ceylanicum, downloaded from the ParaSite database (release 6; ftp://ftp.
wormbase.org/pub/wormbase/parasite/releases/WBPS6/species/ancylostoma_ceylanicum/
PRJNA231479/ancylostoma_ceylanicum.PRJNA231479.WBPS6.CDS_transcripts.fa.gz) [39].
We quantitated gene expression from all of our quality-filtered A. ceylanicum RNA-seq data
sets with Salmon 0.7.2 (https://github.com/COMBINE-lab/salmon/releases/download/v0.7.2/
Salmon-0.7.2_linux_x86_64.tar.gz), generating expression values in Transcripts Per Million
(TPM) and estimating mapped read counts per gene [40]. For Salmon’s index program, we
used the arguments "—no-version-check index—kmerLen 31—perfectHash—type quasi—
sasamp 1"; for Salmon’s quant program, we used the arguments "—libType A seqBias gcBias
numBootstraps 100—geneMap [transcript-to-gene table]", with "—unmatedReads" specifying
the 50-nt single-end data. For gene annotations, we created new Pfam motif annotations with
hmmscan from HMMER version 3.1b2 [41] and the Pfam 31.0 database, using the arguments
"—cut_ga -o /dev/null—tblout [table]" which invoked reliably curated domain-specific thresh-
olds; we also generated new InterPro motif annotations with interproscan.sh from InterProS-
can 5.18–57.0 [42], using the arguments "-dp -hm -iprlookup -goterms". Both Pfam and
InterPro motifs were computed solely for the largest isoform of each gene’s predicted protein
products (downloaded from ParaSite release 6; ftp://ftp.ebi.ac.uk/pub/databases/wormbase/
parasite/releases/WBPS6/species/ancylostoma_ceylanicum/PRJNA231479/ancylostoma_
ceylanicum.PRJNA231479.WBPS6.protein.fa.gz); these largest isoforms were extracted with
get_largest_isoforms.pl using the argument "-t parasite". All other gene annotations were taken
from our previous work [35]. The Perl scripts quality_trim_fastq.pl and get_largest_isoforms.pl
are available from https://github.com/SchwarzEM/ems_perl.
CDS cloning
Adult A. ceylanicum hookworms were collected from the small intestine of a day 22 post-inoc-
ulation (PI) hamster into a 1.5 mL microfuge tube, were rinsed three times with Milli-Q water,
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and then snap-frozen in liquid nitrogen and stored in -80˚C. Tissue homogenization was per-
formed in the same 1.5 mL microfuge tube on liquid nitrogen using a pre-chilled tapered flat
end weighing spatula followed by a pre-chilled micropestle. Total nucleic acid was isolated
with Nucleospin RNA kit (Machery-Nagel) according to the manufacturer’s instructions,
except that on-column DNase treatment was omitted. The total nucleic acid was then treated
with RNase-free DNase I (NEB) according to the manufacturer’s instructions. RNA was pre-
cipitated by addition of 1:10 vol 3 M sodium acetate and 2.5 vol ethanol with O/N storage in
-20˚C. The RNA pellet was washed twice with ethanol and then dissolved in 50 μL Milli-Q
water. cDNA was synthesized with qScript cDNA SuperMix (Quantabio) according to the
manufacturer’s instructions. PCR was performed with Platinum Taq DNA Polymerase High
Fidelity (Invitrogen) according to the manufacturer’s instructions using the following primers:
Aceys0154g3007cdsF and Aceys0154g3007cdsR (AceyCP1), Aceys0532g3038t1cdsF and
Aceys0532g3038t1cdsR (AceyCPL), and Aceys0034g2829t1cdsF and Aceys0034g2829t1cdsR
(AceySKPI3) (Table S1). The PCR products were purified with Monarch PCR and DNA
Cleanup Kit (NEB) and were sequenced at GENEWIZ.
Protein expression in P. pastoris X-33
The validated CDS sequences were sent to Genscript for P. pastoris codon-optimized DNA
synthesis and the CDSs without native signal peptides (AceyCP1, nt 40–1,032; AceyCPL, nt
46–1,032; and AceySKPI3, nt 52–240) were subcloned into pPICZαA in-frame with yeast α-
factor signal. During subcloning polyhistidine tags were added directly 5’ to the CDSs by PCR.
The plasmids were linearized with SacI and transformed into P. pastoris X-33. Single trans-
formed colonies (confirmed by colony PCR) were inoculated into 25 mL Buffered Glycerol-
complex Medium (BMGY) and grown to an OD600 of 3.0. The 25 mL cultures were used to
inoculate 0.5 L BMGY cultures at an OD600 of 1.0, and these cultures were grown to an
OD600 of 3.0. The BMGY cultures were centrifuged and each was resuspended in 2 L of Buff-
ered Methanol-complex Medium (BMMY) distributed into four 2 L baffled flasks, and these
cultures were grown for 4 days. After 4 days of incubation, the BMMY cultures were centri-
fuged, and the clarified supernatants were collected.
Protein purification from X-33 supernatants
rAceyCP1, rAceyCPL and rAceySKPI3 were purified from X-33 culture supernatants by
immobilized metal affinity chromatography using a Ni resin and column (GenScript). Proteins
bound to the resin were washed with Triton X-100 to reduce endotoxin levels to<1 EU/μg.
The eluates were buffer exchanged into PBS (pH 7.4) by dialysis, and then filter sterilized with
0.22 μm Millex-GP Syringe Filters. Endotoxin levels were detected by ToxinSensor Gel Clot
Endotoxin Assay Kit (GenScript). Protein concentrations were determined by Bradford assay
using BSA as standard (GenScript).
SDS-PAGE and Western blots
For SDS-PAGE, 4 μg of each protein was boiled for ~5 min in Pierce Lane Marker Reducing
Sample Buffer (Thermo Fisher) and loaded into a 12% Tris-Glycine mini gel. Electrophoresis
was run for ~2 hr at 100V in a Mini-PROTEAN Tetra Cell (Bio-Rad). Proteins were stained
with Coomassie Blue, and the gels were imaged with a ChemiDoc XRS+ System with Image
Lab Software (Bio-Rad). Molecular weights were estimated in Image Lab from the SDS-PAGE
gels.
For Western blots, immediately after electrophoresis proteins were transferred to PVDF
membranes using a Trans-Blot Turbo Transfer System with RTA Mini LF PVDF Transfer Kit
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(Bio-Rad). The membranes were blocked for 1.5 hr in blocking buffer (3% non-fat dry milk
prepared in PBST). The blocked membranes were washed for 5 min twice with PBST, and
then incubated for 1.5 hr in 6x-His Tag Monoclonal Antibody (HIS.H8) (Invitrogen) diluted
1:2,000 in blocking buffer. The membranes were then washed for 5 min 3 times with PBST,
and then incubated for 1 hr in Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP (Invi-
trogen) diluted 1:3,000 in blocking buffer. The membranes were washed for 5 min 3 times
with PBST, and then incubated in the dark for 5 min in SuperSignal West Pico PLUS Chemilu-
minescent Substrate. The membranes were imaged with a ChemiDoc XRS+ System with
Image Lab Software (Bio-Rad). Signal accumulation mode was used first to find the optimum
exposure time (60 sec), and then the membranes were washed for 5 min with PBST and then
incubated again in substrate. Finally, the membranes were imaged manually with the optimum
exposure times.
Vaccine trials
Vaccines were prepared fresh for each immunization on ice in a total volume of 1.8 mL
(rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel, rAceyCP1/Alhydrogel trial 1) or 2.6 mL
(rAceyCP1/Alhydrogel trial 2) in sterile 5 mL microfuge tubes. Two hundred twenty-five μg
(rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel, rAceyCP1/Alhydrogel trial 1) or 325 μg
(rAceyCP1/Alhydrogel trial 2) of immunogen was diluted up to 1.575 mL (rAceyCPL/Alhy-
drogel, rAceySKPI3/Alhydrogel, rAceyCP1/Alhydrogel trial 1) or 2.275 mL (rAceyCP1/Alhy-
drogel trial 2) in PBS (pH 7.4), and 225 μL ((rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel,
rAceyCP1/Alhydrogel trial 1) or 325 μL (rAceyCP1/Alhydrogel trial 2) of Alhydrogel (Invivo-
Gen) was added. Immunogens were adsorbed to Alhydrogel according to the manufacturer’s
instructions. For Alhydrogel control, 225 μL (rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel,
rAceyCP1/Alhydrogel trial 1) or 325 μL (rAceyCP1/Alhydrogel trial 2) of Alhydrogel was
added to 1.575 mL (rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel, rAceyCP1/Alhydrogel
trial 1) or 2.275 mL (rAceyCP1/Alhydrogel trial 2) of PBS (pH 7.4). Final doses were 25 μg of
protein and 250 μg of aluminum content (per dose).
Hamsters were injected subcutaneously (SC) with insulin syringes (BD) three times with
two-week intervals in the scruff of the neck with 200 μL of vaccine. One week after the final
immunization, hamsters were separated into individual cages, and the individual cages were
randomly arranged on the shelves. Twelve days after the final immunization, peripheral blood
was collected by saphenous venipuncture using PrecisionGlide 20 G x 1” hypodermic needles
(BD) and SAFE-T-FILL Capillary Blood Collection Tubes–Serum (RAM Scientific). Blood was
allowed to clot for at least 30 min at room temperature before centrifugation. The collected
serum was stored in -20˚C until ELISA. Thirteen days after the final immunization, hamsters
were weighed and blood was collected again, but into SAFE-T-FILL Capillary Blood Collection
Tubes–EDTA (RAM Scientific). Blood hemoglobin concentrations (g/dL) were measured with
a STAT-Site M Hgb Hemoglobin Analyzer and Test Cards (Stanbio).
Exactly two weeks after the final immunization hamsters were inoculated with ~150 A. cey-
lanicum L3i by oral gavage. L3i were obtained by coproculture of feces collected from infected
hamsters, and had been stored in the dark at room temperature for <2 weeks in BU buffer (50
mM Na2HPO4, 22 mM KH2PO4, 70 mM NaCl, pH 6.8) plus PSF (100 U/mL penicillin;
100 μg/mL streptomycin; 0.25 μg/mL amphotericin B) before inoculations. This A. ceylanicum
line was originally obtained from Dr. John Hawdon at George Washington University. On day
20 PI, hamsters were weighed and blood hemoglobin concentrations measured as before. On
day 22 PI, hamsters were placed on fecal collection wires overnight. Two layers of moistened
paper towels were placed in the bottoms of the cages underneath the fecal collection wires. On
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day 23 PI, hamsters were euthanized by CO2 overdose and cervical dislocation (according to
IACUC protocol). Small intestines were removed, longitudinally sectioned, and incubated in
Hank’s Balanced Salt Solution (HBSS; Thermo Fisher) for 45 min at 37˚C, 5% CO2. Hook-
worm burdens were counted under a stereomicroscope. Fecal pellets were collected from the
cage of each hamster, and FECs were measured using a McMaster chamber (Hausser
Scientific).
Serum ELISA
Immunogens were coated overnight at 4˚C onto Nunc MaxiSorp flat-bottom 96-well plates at
5 μg/ml in carbonate/bicarbonate (100 mM), pH 9.6 coating buffer (100 μL/well). Wells were
washed three times with PBST (200 μL/well), and then blocked for 1.5 hr in blocking buffer
(5% non-fat dry milk in PBST) (200 μL/well) at room temperature. Wells were washed two
times with PBST (200 μL/well), and then hamster sera serially diluted in blocking buffer was
incubated (100 μL/well) for 1.5 hr at room temperature. Wells were washed three times with
PBST (200 μL/well), and then Peroxidase AffiniPure Goat Anti-Syrian Hamster IgG (H+L)
(Jackson ImmunoResearch) was diluted 1:5,000 in blocking buffer and incubated in the wells
(100 μL/well) for 1.5 hr at room temperature. Wells were washed three times with PBST
(200 μL/well), and 100 μL of 1-Step Ultra TMB-ELISA Substrate Solution (Thermo Fisher) was
incubated in the wells for 30 min. Then 100 μL of sulfuric acid (2 M) was added to the wells,
and A450 was measured with a Tecan Safire plate reader.
In multiple pilot experiments, we tested Rabbit anti-Syrian hamster IgM-HRP (Rockland),
Goat anti-Mouse IgA-HRP (Thermo Fisher; [43]) and Goat anti-Mouse IgE-HRP (Thermo
Fisher) in ELISAs to soluble A. ceylanicum hookworm extract (HEX; [43]) using serum from
infected and drug-cleared hamsters. Anti-Syrian hamster IgM-HRP gave extremely high back-
ground to HEX with serum from uninfected hamsters. Neither anti-Mouse IgA-HRP or anti-
Mouse IgE-HRP reacted to HEX with serum from infected hamsters, while Goat anti-Syrian
hamster IgG (mentioned above) reacted strongly to HEX only with serum from infected ham-
sters. Thus, only Goat anti-Syrian hamster IgG was useful for serum ELISAs.
In vitro hookworm antiserum toxicity assays
A. ceylanicum adult hookworms were collected from the small intestines of initially naïve ham-
sters on day 17 PI. Small intestines were longitudinally sectioned and incubated for 2 hr in
HBSS pre-warmed at 37˚C in a mini Baermann Funnel apparatus. Every 20–30 min the small
intestines were moved around with forceps. The HBSS containing motile hookworms that had
migrated through the wire mesh and settled at the bottom of the funnel was poured into a
petri dish, and the motile hookworms were hand-picked with a worm picker into Milli-Q
water, and rinsed three times. Hookworms were hand-picked into individual wells of a 96-well
plate (two hookworms per well) containing 50 μL of HCM with 50% heat-inactivated fetal
bovine/calf serum [44] replaced by hamster serum (mHCM: 49.5% RPMI 1640 Medium con-
taining L-glutamine without Phenol Red Indicator [Thermo Fisher]; 49.5% hamster serum;
1% 100X PSG [100 U/mL penicillin; 100 μg/mL streptomycin; 0.292 mg/mL L-glutamine;
Thermo Fisher]). Each hamster serum group included three wells (two hookworms/well for a
total of six hookworm adults scored per group), and the average motility for the three wells
was calculated using a standard 3–0 motility index assay (3 = highly motile; 2 = less motile;
1 = motile only when stimulated by touch; 0 = immotile) [45–47]. Motility was monitored for
76 hr (once per day). To address any concerns about subjectivity, each replicate well for each
condition was randomized in the setup so that the investigator was blinded as to which well
contained which condition during the scoring process.
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Ex vivo mitogenic splenocyte cytokine assay
Another set of hamsters was vaccinated with rAceyCP1/Alhydrogel and Alhydrogel control
exactly as before in the vaccine trials. Serum IgG responses were evaluated by ELISA as before
using A450 readings at 1:100 serum dilutions. Two weeks after the final immunization ham-
sters were euthanized as before. Spleens were removed with ethanol-sterilized forceps and
transferred to 5 mL DMEM-10 cell culture medium (89.5% DMEM [Dulbecco’s Modification
of Eagle’s Medium; Mediatech]; 9.5% fetal calf serum [Thermo Fisher]; 1% 100X PSG; steril-
ized with 0.22 μm filter; stored in 4˚C) in 60-mm petri dish on ice. Each spleen was cut into
three pieces with ethanol-sterilized surgical scissors. Each spleen piece was smashed individu-
ally between two frosted microscope slides and rinsed back into the petri dish, removing any
remaining solid tissue left on the slide with forceps. Each spleen material in DMEM-10 was
passed through syringe needle series of 18, 22, and 26 G (BD) to prepare the splenocyte sus-
pension that was collected into a 15-mL conical centrifuge tube pre-chilled on ice. Splenocyte
suspensions were centrifuged at 1,500 rpm for 5 min at 4˚C. The supernatant was discarded
and cell pellet resuspended in 1 mL ACK Lysing Buffer (Thermo Fisher) and incubated for 10
min at room temperature. Immediately after, 9 mL of DMEM-10 was added and then centri-
fuged as before. Each splenocyte suspension was resuspended in 2 mL DMEM-10, and 1 mL
was transferred into each of 2 different wells of a 48-well plate. For each splenocyte suspension,
25 μg of rAceyCP1 was added to one well and PBS (pH 7.4) to the other well. Splenocytes were
stimulated for 48 hr at 37˚C, 5% CO2.
Stimulated splenocytes were transferred to 1.5 mL microfuge tubes and centrifuged as
before. Supernatants were discarded, cell pellets were resuspended in lysis buffer and vortexed,
and RNA was isolated as before. Either 10 μg (γ-actin, IFN-γ, IL17A, IL10, and TGF-β) or
50 μg (IL4, IL5, IL13, and IL21) of RNA (as determined in primer efficiency tests) was used as
template for qRT-PCR using qScript One-Step SYBR Green qRT-PCR Kit (Quantabio)
according to the manufacturer’s instructions. Protocol: 49˚C for 10 min, 95˚C for 5 min, 35
cycles of 95˚C for 15 sec and 60˚C for 45 sec. Amplification specificities were verified by melt-
ing curve analysis. Melting curve protocol: 95˚C for 1 min, 55˚C for 10 sec and a slow tempera-
ture ramp from 55 to 95˚C. The primer sets (Table S1; [48]) were pre-validated with mean ± S.
D. amplification factors of 2.0 ± 0.3 in primer efficiency tests using the same sample type.
qRT-PCR was performed on an Eppendorf Mastercycler RealPlex2. Four technical replicates
were included for every primer set on each RNA sample. Minus reverse transcriptase reactions
were also run on every RNA sample for every primer set, and this indicated that the RNA sam-
ples had undetectable levels of gDNA. γ-actin was used as reference. We had hoped to look at
even more cytokines by qRT-PCR, but we did not have RNA for all biological replicates. Data
were analyzed using the 2-ΔΔCT method [49].
Statistical analysis
All data analyses were plotted in Prism 7 (GraphPad Software). For serum IgG endpoint titers,
plotted are the inverses of the final serum dilutions for each serum sample from each hamster
within each vaccine group that gave an A450 reading that is>3 S.D. from the mean A450 read-
ing for naïve hamster sera (n = 8) at the same dilution. For hookworm burden, mean indicates
the mean hookworm burden amongst all hamsters in each vaccine group. For FECs (eggs/g),
mean indicates the egg count per group from all cages in the group at a given time point. For
Δweight and Δhemoglobin, mean indicates the mean Δweight and Δhemoglobin amongst all
hamsters in each vaccine group. For motility index, mean indicates the mean motility amongst
all wells (2 hookworms/well, 3 wells/group) in the group at a given time point. For serum IgG
A450, plotted are the raw A450 readings for each serum sample from each hamster per vaccine
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group at 1:100 dilution with average Alhydrogel background subtracted. For relative fold
change in mRNA, mean indicates the mean relative fold change in mRNA in splenocytes
amongst all hamsters in each vaccine group.
Statistical 2-sample comparisons between experimental and control vaccine groups were
carried out by one-tailed Mann-Whitney, with the hypothesis that successful vaccination will
result in decreases in infection parameters (worm burdens, fecal egg counts) and improve-
ments in measurements of sequelae (weight, hemoglobin). Nearly identical statistical results
were obtained using student’s t test. All comparisons between multiple experimental groups
with control (i.e., Alhydrogel alone) group were carried out using one-way ANOVA with Dun-
nett’s post-hoc test, comparing each group to control. Significant correlations in linear regres-
sion analyses (i.e., if slopes are significantly non-zero) were determined by F test.
Results
Production of three vaccine antigen candidates
Transcriptomic analyses revealed that the hookworm A. ceylanicum upregulates proteases and
protease inhibitors during infection, which are likely to be important for successful parasitism
[35]. Proteases are thought to help hookworms dig through their host’s tissues, destroy pro-
teins needed for the host’s immune response, and digest proteins in the host’s blood [50]. Pro-
tease inhibitors are thought to block host proteases needed for the immune response as well
[51]. These proteases and protease inhibitors therefore defined an initial set of vaccine candi-
dates and included putatively secreted cathepsin B-like proteases (CPs), which have homologs
in other strongylids, and a previously undescribed family of putatively secreted small Kunitz-
type protease inhibitors (SKPIs) that are strongly upregulated in adult hookworms [35].
We successfully cloned full-length cDNAs for A. ceylanicum CP1 (rAceyCP1; AceyCP1
[genomic name, Acey_s0154.g3007]), AceyCPL (rAceyCPL [Acey_s0532.g3038]), and
AceySKPI3 (rAceySKPI3 [Acey_s0034.g2829]) (Fig 1A). We expressed the proteins in Pichia
pastoris and purified them using standard protocols (Fig 1B–1E; see Methods for details). P.
pastoris expression was used for previous hamster-hookworm vaccine trials [52,53]. Since the
hookworm intestine is a key target of protective vaccine antigens, we examined expression of
these genes in published male hookworm intestinal transcriptomic data (Table S2) [38].
AceyCP1 is very strongly expressed in the male intestine at 11,600 transcripts per million
(TPM), making it 1.2% of all transcripts in that tissue. AceyCPL and AceySKPI3 are present
but considerably more weakly expressed in the male hookworm intestine at 52 TPM and 1.7
TPM respectively. Neither AceyCP1 nor AceyCPL are expressed in L3i (0.15 and 0 TPM
respectively). AceySKPI3 has modest expression in L3i (14 TPM), but this is less than or com-
parable to expression levels for the A. ceylanicum homologs of APR1 and GST1 (AceyAPR1
[Acey_s0242.g3404], 744 TPM; AceyGST1 [Acey_s0110.g143], 44 TPM), which in N. ameri-
canus are considered acceptable vaccine candidates.
By SDS-PAGE and Western blot, three bands were observed for rAceyCP1 at ~42, ~44 and
~46 kDa (Fig 1B and 1C), two bands were observed for rAceyCPL at ~40 and ~42 kDa (Fig 1B
and 1C), and two bands were observed for rAceySKPI3 at ~12 and ~19 kDa (mostly single
band at ~12 kDa; Fig 1D and 1E). AceyCP1 and AceyCPL are proenzymes containing N-ter-
minal pro-regions and a CP domain (Fig 1A). Two N-glycosylation sites were identified in
AceyCP1 with NetNGlyc 4.0 (http://www.cbs.dtu.dk/services/NetNGlyc) [54], both of which are
located in its CP domain near putative active site residues (Fig 1A). One N-glycosylation site
was identified in AceyCPL within its pro-region (Fig 1A). These predicted N-glycosylation
sites match up with the observed banding patterns (Fig 1B and 1C). NetNGlyc 4.0 did not
identify any potential N-glycosylation sites in AceySKPI3 (Fig 1A). Treatment of rAceyCP1
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and rAceyCPL with endoglycosidase (Endo) H resulted in shifts to a single ~42-kDa band for
rAceyCP1 and a single ~40-kDa band for rAceyCPL (Fig 1B and 1C). According to these
results, rAceyCP1 consists of unglycosylated, monoglycosylated, and biglycosylated forms,
while rAceyCPL consists of unglycoslyated and monoglycosylated forms. The weak ~19-kDa
upper band in rAceySKPI3 could be a form of dimer or a monomer with other post-
Fig 1. Production of secreted rAceyCP1, rAceyCPL and rAceySKPI3 from Pichia pastoris. (A) Schematic diagrams of rAceyCP1, rAceyCPL and rAceySKPI3.
Amino acid positions are indicated above. Putative active site residues are indicated below. N-glycosylation sites are indicated above at their approximate locations
with the glycosylated asparagine colored blue. AceyCPL and AceyCP1 share 54% amino acid identity. (B) SDS-PAGE of untreated and endoglycosidase (Endo) H-
treated rAceyCP1 and rAceyCPL (Coomassie Blue image). (C) Western blot of untreated and Endo H-treated rAceyCP1 and rAceyCPL (grayscale image). (D)
SDS-PAGE analysis of rAceySKPI3 (grayscale image). (E) Western blot of rAceySKPI3 (inverted grayscale image).
https://doi.org/10.1371/journal.pntd.0007345.g001
Fig 2. Vaccine trial timeline. Abbreviations—IgG: serum immunoglobulin G titers determined by ELISA; Hgb: blood hemoglobin
concentration determined; weights: hamsters weighed; Δweights, change in weights after hookworm infection calculated after second weight
taken; ΔHgb, change in blood hemoglobin concentrations after hookworm infection calculated after second hemoglobin measurement
taken; FECs, overnight fecal egg counts determined.
https://doi.org/10.1371/journal.pntd.0007345.g002
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translational modification(s). Densitometric analysis determined all three recombinant pro-
teins to be>95% pure.
rAceyCPL/Alhydrogel and rAceySKPI3/Alhydrogel induce consistently
high serum IgG titers but are not protective
rAceyCPL was adsorbed to Alhydrogel and injected SC into Syrian hamsters three times at
two-week intervals (Fig 2, timeline). Twelve days after the final immunization (Fig 2),
rAceyCPL serum IgG titer was determined by indirect enzyme-linked immunosorbent assay
(ELISA). All rAceyCPL/Alhydrogel vaccinates (8/8) had serum IgG titers above background in
Alhydrogel controls ranging from 100,000 to�500,000 (Fig 3A). Hamsters were infected with
~150 A. ceylanicum third stage infective larvae (L3i) exactly two weeks after the final immuni-
zation (Fig 2). At day 23 post-inoculation (PI), the number of hookworms in the small intes-
tines (hookworm burden) were counted at necropsy, and feces were collected for fecal egg
counts (FECs; hookworm eggs shed per g of feces). Mean hookworm burden and FEC were
statistically similar between rAceyCPL/Alhydrogel vaccinates and Alhydrogel controls (Fig 3B
and 3C), indicating that parasitism was unaffected by vaccination. As markers for the clinical
pathology caused by hookworm infection, changes in weight and hemoglobin (Δweight and
Δhemoglobin) were evaluated (on day 20 post-inoculation (PI) prior to necropsy; Fig 2). Con-
sistent with hookworm burden and FEC, mean Δweight and Δhemoglobin were statistically
similar between rAceyCPL/Alhydrogel vaccinates and Alhydrogel controls (Fig 3D and 3E),
indicating that clinical pathology was also unaffected by vaccination.
All rAceySKPI3/Alhydrogel vaccinates (8/8) had serum IgG titers above background in
Alhydrogel controls ranging from 100,000 to, remarkably,�10,000,000 (Fig 4A). However, as
with rAceyCPL/Alhydrogel, rAceySKPI3/Alhydrogel vaccination did not significantly alter
hookworm parasitism (Fig 4B and 4C), or clinical pathology (Fig 4D and 4E) compared to
Alhydrogel controls. Thus, these results indicate that although both rAceyCPL/Alhydrogel and
rAceySKPI3/Alhydrogel induce high serum IgG titers above background with 100% responder
rates, these antigens are not protective.
rAceyCP1/Alhydrogel induces intermediate serum IgG titers and
responders are protected against hookworm infection
Two independent vaccine trials were conducted for rAceyCP1, the first with eight animals per
group and the second with 12 animals per group. In trial 1, 5/8 vaccinates (62.5%) had
rAceyCP1-specific serum IgG titers above background in Alhydrogel controls ranging from
4,000–10,000 (Fig 5). In trial 2, 7/12 vaccinates (58.3%) had rAceyCP1 serum IgG titers above
background in Alhydrogel controls ranging from 2,000–20,000 (Fig 5). In trial 1 and trial 2,
hookworm burdens were decreased in rAceyCP1/Alhydrogel vaccinates compared to Alhy-
drogel control vaccinates by a mean of 31% and 19% respectively, achieving statistical signifi-
cance in trial 1 (Fig 6A) and nearly achieving statistical significance in trial 2 (Fig 6A).
Significant decreases in FECs were seen in both trials (Fig 6B). In trial 1 and trial 2, respec-
tively, FECs were significantly decreased in rAceyCP1/Alhydrogel vaccinates compared to
Alhydrogel control vaccinates by a mean of 46% and 26%.
Vaccination with rAceyCP1 also generally led to improvements of hookworm sequelae.
Δweight was signficantly improved in rAceyCP1/Alhydrogel vaccinates by 7.6 g (Syrian ham-
sters weigh around 115 g at this age; ~12 weeks) compared to Alhydrogel controls in trial 1
(Fig 6C), and there was a trend of 2.8 g toward improved Δweight in trial 2 (Fig 6C). The
Δhemoglobin was statistically similar between rAceyCP1/Alhydrogel vaccinates and Alhydro-
gel controls in both trials (Fig 6D).
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In both vaccine trials, we noticed that rAceyCP1 serum IgG responders were qualitatively
more protected than nonresponders (Fig 6; compare blue and orange data points). We hypothe-
sized that the responders were protected from infection and sequelae whereas the nonrespond-
ers were not. Thus, we reanalyzed them as separate groups, and compared them to Alhydrogel
controls. Strikingly, in trial 1, hookworm burden was dramatically and significantly decreased
in responders by 54% compared to Alhydrogel controls (Fig 7A), whereas nonresponders
showed no protection compared to Alhydrogel controls (Fig 7A). In trial 2, hookworm burden
was dramatically and significantly decreased in responders by 40% compared to Alhydrogel
controls (Fig 7A), whereas nonresponders showed no protection compared to Alhydrogel con-
trols (Fig 7A). Protection from infection based on hookworm burdens was mirrored in FECs.
In trial 1, FECs were dramatically and significantly decreased in responders by 66% compared
to Alhydrogel controls (Fig 7B), whereas nonresponders showed no protection compared to
Alhydrogel controls (Fig 7B). Accordingly, in trial 2, FECs were dramatically and significantly
decreased in responders by 54% compared to Alhydrogel controls (Fig 7B), whereas nonre-
sponders showed no protection compared to Alhydrogel controls (Fig 7B). Sequelae based
on Δweight were also improved. In trial 1, responders had a dramatically and significantly
improved Δweight of 9.6 g compared to Alhydrogel controls (Fig 7C), whereas nonresponders
showed no improved Δweight compared to Alhydrogel controls (Fig 7C). In trial 2, responders
had a dramatically and significantly improved Δweight of 6.0 g compared Alhydrogel controls
Fig 3. rAceyCPL/Alhydrogel vaccine trial. (A) rAceyCPL serum IgG titers in Alhydrogel controls and rAceyCPL/Alhydrogel vaccinates. Dotted lines indicate
the inverse of serum dilutions tested. (B) Comparison of mean hookworm burden between rAceyCPL/Alhydrogel and Alhydrogel control vaccinates. (C)
Comparison of mean FECs between rAceyCPL/Alhydrogel and Alhydrogel control vaccinates. (D) Comparison of mean change in weight after hookworm
infection between rAceyCPL/Alhydrogel and Alhydrogel control vaccinates. (E) Comparison of mean change in hemoglobin concentration after hookworm
infection between rAceyCPL/Alhydrogel and Alhydrogel control vaccinates. Numbers above bars indicate P values for comparison. (B-E) Error bars here and
all figures indicate standard error.
https://doi.org/10.1371/journal.pntd.0007345.g003
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(Fig 7C), whereas nonresponders showed no improved Δweight compared to Alhydrogel con-
trols (Fig 7C). In trials 1 and 2, responders had improved Δhemoglobin by 2.2 g/dL and 2.0 g/
dL respectively, although neither was statistically significant (Fig 7D).
A complete summary of the efficacy results from rAceyCP1/Alhydrogel vaccine trials 1 and
2 is given in Table 1, with the two immunogens currently being tested in phase 1 clinical trials
included for comparisons. Linear regression analysis was performed on the data to investigate
the correlation between rAceyCP1 serum IgG titer and changes in sequelae and parameters of
infection. These analyses determined that, in both vaccine trials, rAceyCP1 serum IgG titer
highly significantly correlated with all four measures of protection, including Δhemoglobin
(Fig 8). Moreover, serum IgG titers of 10,000–20,000 in the two trials (n = 4) gave a mean of
64.6% decreased hookworm burden and 76.9% decreased FECs compared to Alhydrogel con-
trols. These findings indicate that when rAceyCP1 serum IgG titer is sufficiently induced,
rAceyCP1/Alhydrogel is a highly protective hookworm vaccine.
Antisera from rAceyCP1/Alhydrogel responders significantly reduces adult
hookworm motility in vitro
We hypothesized that serum IgG might be at least partly responsible for vaccine-induced pro-
tections in rAceyCP1/Alhydrogel serum IgG responders. As a first test for this hypothesis, we
Fig 4. rAceySKPI3/Alhydrogel vaccine trial. (A) rAceySKPI3 serum IgG titers in Alhydrogel controls and rAceySKPI3/Alhydrogel vaccinates. Dotted lines indicate the
inverse of serum dilutions tested. (B) Comparison of mean hookworm burden between rAceySKPI3/Alhydrogel and Alhydrogel control vaccinates. (C) Comparison of
mean FEC between rAceySKPI3/Alhydrogel and Alhydrogel control vaccinates. (D) Comparison of mean change in weight after hookworm infection between
rAceySKPI3/Alhydrogel and Alhydrogel control vaccinates. (E) Comparison of mean change in hemoglobin concentration after hookworm infection between
rAceySKPI3/Alhydrogel and Alhydrogel control vaccinates. (B, C) For rAceySKPI3/Alhydrogel, n = 7 as 1 vaccinate died on day 21 PI (i.e., one day after obtaining
Δweight (D) and Δhemoglobin (E); hookworm burden and FEC were determined on day 23 PI).
https://doi.org/10.1371/journal.pntd.0007345.g004
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incubated adult A. ceylanicum hookworms obtained from naïve hamsters in a modified hook-
worm culture medium (mHCM) containing 50% antisera from rAceyCP1/Alhydrogel serum
IgG responders and nonresponders, as well as rAceyCPL/Alhydrogel vaccinates and Alhydro-
gel controls. We scored motility over a period of 76 hr; scoring was performed blind relative to
treatment condition to prevent bias. Hookworm motility was significantly reduced by 76 hr in
rAceyCP1/Alhydrogel serum IgG responder antisera by a mean of 33.3% compared to in Alhy-
drogel control sera (Fig 9). Conversely, hookworm motilities in serum IgG non-responder
antisera and rAceyCPL/Alhydrogel antisera were reduced by just 5.6% and were statistically
similar to Alhydrogel control sera (Fig 9), demonstrating specificity of the activity seen above.
Thus, the unique toxicity of antisera alone from rAceyCP1/Alhydrogel serum IgG responders
is consistent with the observed protections.
rAceyCP1/Alhydrogel induces antigen-specific Th2 cytokines in serum IgG
responders
Vaccination with rAceyCP1/Alhydrogel induced protection that was highly correlated with
serum IgG titer, and found to intoxicate/reduce adult hookworm motility in vitro. In order to
gain an understanding of the adaptive, cellular immune responses induced in rAceyCP1/Alhy-
drogel vaccinates, eight hamsters were vaccinated with rAceyCP1/Alhydrogel exactly as in tri-
als 1 and 2. Peripheral blood was collected one week after the final immunization to measure
serum IgG responses. Necropsy was performed exactly two weeks after the final immunization
(i.e., at the exact time vaccinates were infected with L3i in trials 1 and 2), and splenocyte sus-
pensions were prepared. rAceyCP1/Alhydrogel and Alhydrogel control splenocytes were stim-
ulated ex vivo with rAceyCP1 or PBS. Total RNA was then isolated and used directly as
Fig 5. rAceyCP1 serum IgG titers in rAceyCP1/Alhydrogel and Alhydrogel control vaccinates. Blue dots indicate rAceyCP1 serum IgG responders (IgG
titers above background levels found in Alhydrogel controls). Orange dots indicate rAceyCP1 serum IgG nonresponders. Dotted lines are indicated at the
inverses of each serum dilution tested.
https://doi.org/10.1371/journal.pntd.0007345.g005
A protective intestinal cysteine protease antigen of human hookworm
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007345 April 22, 2019 14 / 26
template for quantitative real-time reverse transcription (qRT)-PCR using pre-validated
primer sets [48] for the following cytokines: IFN-γ (Th1); IL4, IL5, IL13 (Th2); IL17A (Th17);
IL21 (Th17/Tfh); IL10, TGF-β (Treg) (S1 Fig).
rAceyCP1/Alhydrogel vaccinates (4/8) gave rAceyCP1 serum IgG responses (raw A450
readings) above background in Alhydrogel controls in serum diluted 1:100 (Fig 10A).
rAceyCP1-stimulated splenocytes from rAceyCP1/Alhydrogel IgG responders (n = 4) resulted
in elevated levels of all three Th2 cytokine mRNAs (IL4, IL5 and IL13) that were significantly
greater than in stimulated splenocytes from Alhydrogel controls (n = 5; Fig 10B). No other
cytokines were elevated in splenocytes from rAceyCP1/Alhydrogel serum IgG responders at
levels that were significantly greater than in Alhydrogel control, indicating a highly specific,
canonical Th2 cytokine recall response. Also, all cytokines in stimulated splenocytes from
rAceyCP1/Alhydrogel IgG nonresponders were statistically similar to Alhydrogel control
(Fig 10B).
Discussion
We demonstrate here that the highly expressed, substantially intestine-enriched cathepsin B
cysteine protease, AceyCP1, is a promising protective antigen candidate for vaccination
against A. ceylanicum hookworm infection in Syrian hamsters. Two antigens (AceyCPL,
AceySKPI3) with much lower transcript levels in the adult A. ceylanicum intestine compared
to AceyCP1 were not protective (Figs 3 and 4). These data are supportive of the value of using
intestinal expression to prioritize antigen candidates.
Fig 6. Efficacy results for rAceyCP1/Alhydrogel vaccine trials 1 and 2 with all animals combined. (A) Comparison of mean hookworm burden between rAceyCP1/
Alhydrogel and Alhydrogel control vaccinates. Blue dots indicate serum IgG responders, orange dots indicate serum IgG nonresponders (see Fig 5). (B) Comparison of
mean FEC between rAceyCP1/Alhydrogel and Alhydrogel control vaccinates. (C) Comparison of mean change in weight after hookworm infection between rAceyCP1/
Alhydrogel and Alhydrogel control vaccinates. (D) Comparison of mean change in hemoglobin concentration after hookworm infection between rAceyCP1/Alhydrogel
and Alhydrogel control vaccinates.
https://doi.org/10.1371/journal.pntd.0007345.g006
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Other intestinal CPs were shown to be protective against other blood-feeding gastrointesti-
nal nematodes (canine hookworm A. caninum, small ruminant parasite H. contortus, N. ameri-
canus hookworms) in animal hosts (dogs, sheep, hamsters respectively) [29,55–58], albeit not
to the extent that we report here for AceyCP1 (e.g., vaccination with N. americanus CP2 gave
29% reduction in worm burdens in hamsters). Interestingly, intestinal CPs were shown not to
be protective against an STN parasite of cattle that does not ingest blood, Ostertagia ostertagi
Fig 7. Efficacy results for rAceyCP1 serum IgG responders and nonresponders analyzed as separate groups. Comparisons between rAceyCP1/Alhydrogel
serum IgG responders (blue dots) and serum IgG nonresponders (orange dots) with Alhydrogel controls (black dots) of (A) mean hookworm burdens, (B)
mean FEC, (C) mean change in weight after hookworm infection and (D) mean change in hemoglobin concentration after hookworm infection R, responders;
NR, nonresponders.
https://doi.org/10.1371/journal.pntd.0007345.g007
Table 1. Summary of the mean efficacy results from rAceyCP1/Alhydrogel vaccine trials and comparison to clinical hookworm antigen candidates.
vaccine group compared to adjuvant Change in burden Change in FEC Change in weight (g) Change in Hg (g/dL)
rAceyCP1_1—all Alhydrogel -30.7%� -46.7%� +7.6�� -0.1
rAceyCP1_1—R Alhydrogel -53.8%�� -65.5%� +9.6� +2.2
rAceyCP1_2—all Alhydrogel -18.8% -25.7%� +2.8 +0.4
rAceyCP1_2—R Alhydrogel -40.1%�� -53.7%��� +6.0�� +2.0
rAcanAPR1—Ra ASO3 -33.0% -70.0%� n/a +3.0�
rAcanGST1—Rb ASO3 -39.4% -32.3% n/a n/a
� P < 0.05.
�� P < 0.01.
��� P < 0.001; No asterisk indicated not significant at P<0.05.
aLoukas et al. [27] vaccine trial in beagles; only published trial that thoroughly reported efficacy (hookworm burden, fecal egg count [FEC] and a measure of clinical
pathology), and immunogenicity for APR1. rAcanAPR1 gave 100% responder (R) rate with serum IgG2 titer of ~121,500 and IgG1 titer of ~13,500.
bZhan et al. [26] vaccine trial in beagles; only published trial that reported multiple measures of protection (hookworm burden and FEC), and immunogenicity for
GST1. rAcanGST1 gave 100% responder rate with serum IgG2 titer of ~40,500 and IgG1 titer of ~13,500. For comparisons, rAceyCP1 responders gave serum IgG titers
of only 4,000–10,000 in trial 1, and only 2,000–20,000 in trial 2. Additional abbreviations: Hg: Hemoglobin; R, responders; NR, nonresponders; Acan, A. caninum.
https://doi.org/10.1371/journal.pntd.0007345.t001
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[59,60], whereas CPs in O. ostertagi ES products were shown to be protective [59,61]. More-
over, recently, IgG induced by vaccination with whole worm extracts of Ascaris suum (another
non-blood-feeding STN) was determined (in IgG transfer experiments) to be protective
against infection [62]. Furthermore, O. ostertagi intestinal CP components in a larger native
protein complex did cross-protect against H. contortus in vaccinated sheep [60]. These impor-
tant CP enzymes are therefore vulnerable antigens that can be accessed in the gut only by
immune factors that are ingested in the blood. Previous studies of intestinal CPs of blood-feed-
ing STNs have localized the CPs within the worm intestinal lumen with serum IgG from vacci-
nated hosts, and serum IgG has been implicated as the effector component that neutralizes CP
digestion of the blood meal [55,56,58,63,64]. However, our finding that AceyCPL vaccination
gave a strong immune response but no protection confirms that not all cathepsin B cysteine
protease antigens are useful for vaccination.
rAceyCP1/Alhydrogel serum IgG responders had dramatically decreased hookworm bur-
dens, FECs, and weight losses in two different vaccine trials compared to Alhydrogel controls,
whereas nonresponders did not (Fig 7, Table 1). rAceyCP1/Alhydrogel is a highly protective
vaccine, reducing hookworm burdens and FECs by ~50% and ~60%, respectively, in respond-
ers (Fig 7, Table 1), and ~65% and ~77%, respectively, when serum IgG titers were�10,000.
Although there were moderately decreased blood losses in responders compared to Alhydrogel
controls (Fig 7, Table 1), these results were not significant. On the other hand, blood loss was
highly negatively correlated with rAceyCP1 serum IgG titer (Fig 8).
rAceyCP1-induced protection is among the highest seen to date of current hookworm anti-
gens (Table 1). Consistently, AceyCP1 is expressed 220 and 6,800 times more strongly in the A.
ceylanicum intestine compared to AceyAPR1 and AceyGST1 (11,600 TPM versus 52 and 1.7
TPM, respectively) (Table S2). Furthermore, AceyCP1 is almost completely unexpressed in L3i
(0.15 TPM), while AceyAPR1 and AceyGST1 have significant expression levels in L3i (744 and
Fig 8. Linear regression of two measures of sequelae and two measures of infection status by rAceyCP1 serum IgG titer. (A-D) Vaccine trial 1. (E-H)
Vaccine trial 2.
https://doi.org/10.1371/journal.pntd.0007345.g008
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44 TPM, respectively). Thus, AceyCP1 is unlikely to be recognized by IgE and to induce urti-
carial reactions in previously exposed people from hookworm endemic regions [24], since L3i
is the predominant IgE-reactive stage [65]. Although we cannot rule out effects from different
adjuvants, hosts, and Ancylostoma species of vaccine studies carried out to date, rAceyCP1 is
clearly a positive addition to the hookworm vaccine antigen arsenal.
Antisera from rAceyCP1/Alhydrogel responders, but not from nonresponders or
rAceyCPL/Alhydrogel vaccinates, reduced adult A. ceylanicum motility in vitro as early as 24
hr, and was significant by 76 hr (Fig 9). These results are consistent with a model whereby neu-
tralizing serum IgG inhibit AceyCP1 blood digestion within the hookworm gut, thus leading
to starvation—comparable to models for other gut protease antigens of blood-feeding STNs
[25,27,56,58,63].
We observed Th2-specific cytokine recall responses in stimulated splenocytes from
rAceyCP1 responders ex vivo that highly correlated with serum IgG titer (Fig 10). Our findings
reinforce the notion that neutralizing IgG in serum (likely assisted by Th2 cytokines) is the
protective component to gut antigens in blood-feeding STNs.
Vaccinated hamsters in trials 1 and 2 gave ~60% responder rates (Fig 5). Clearly, a major
focus in the future will be to improve responder rates, and rAceyCP1 has the potential to teach
us more about how to make a better hookworm vaccine. The ~40% nonresponder rate could
be due to a number of factors. First, rAceyCP1 was expressed as a secreted, partially glycosy-
lated protein in P. pastoris yeast consisting of unglycosylated, monoglycosylated and biglycosy-
lated forms with relative abundances as follows: biglycosylated > unglycosylated >
monoglycosylated (Fig 1A–1C). Glycosylation of rAceyCP1 may play an important role in the
Fig 9. Antisera specifically from rAceyCP1/Alhydrogel IgG responders reduce adult hookworm motility in vitro.
Motility of hookworms in different hamster sera over time. Adult A. ceylanicum hookworms were collected from naïve
(unvaccinated) hamsters and incubated for 76 h in different hamster sera. Motility was scored using a motility index
(see Materials and Methods). Shown is the mean motility and standard error. � P = 0.013.
https://doi.org/10.1371/journal.pntd.0007345.g009
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IgG nonresponder rate and/or intermediate titers in responders. It has been hypothesized that
proper antigen glycosylation plays a critical role in vaccine efficacy of antigens against other
gastrointestinal nematode parasites (reviewed in [66]). Expressing rAceyCP1 in other systems
with other glycosylation patterns is therefore an important next step. Another potential con-
tributing factor to the ~40% nonresponder rate and intermediate rAceyCP1 serum IgG titers
in responders is major histocompatibility complex (MHC) class II (MHC-II) allelic variation
in the outbred hamster colony, which would give variable Th cell responses [67]. Envigo main-
tains their hamster colony as outbred by non-sib matings and claims that due to high litter
average and reproductive vigor, there should be a diversity of MHC alleles segregating in the
colony.
In conclusion, rAceyCP1/Alhydrogel is a highly protective vaccine against A. ceylanicum
hookworm infection in Syrian hamsters when serum IgG is sufficiently induced, which likely
requires help from Th2 cytokines. Serum IgG may target AceyCP1 within the gut, thereby neu-
tralizing hookworm digestion of the blood meal. Efforts are underway to improve rAceyCP1
neutralizing IgG responder rate and titers, efforts that will ultimately improve translation to
humans. Hookworm is among the most disabling parasitic diseases of the developing world,
and our findings provide important information for advancing hookworm vaccine
development.
Supporting information
S1 Table. Primers. [�]Published by Espitia et al. [48]; primers sets for the other cytokines had
to be redesigned and validated by us (S1 Fig), because Espitia et al. [48] primer sets did not
work for our sample type.
(DOCX)
Fig 10. Assessment of rAceyCP1 splenic cytokine recall responses. (A) Serum IgG ELISA for rAceyCP1/Alhydrogel vaccinates. Reported are the raw
absorbances at 450 nm (A450) using 1:100 serum dilutions with background subtracted (average absorbance of Alhydrogel alone). Orange dots indicate
rAceyCP1 serum IgG nonresponders (NRs). Blue dots indicate rAceyCP1 serum IgG responders (Rs). (B) qRT-PCR of cytokine mRNA transcripts in total
RNA isolated from splenocytes collected from Alhydrogel controls (black bars; n = 5), rAceyCP1/Alhydrogel serum IgG responders (R) (blue bars; n = 4 see
(A)), and rAceyCP1/Alhydrogel serum IgG nonresponders (NR) (orange bars; n = 4 see (A)). Splenocytes were stimulated with rAceyCP1 or PBS. Reported are
the mRNA fold changes in rAceyCP1 relative to PBS stimulated. Data were normalized to actin. ��� P = 0.0007; � P = 0.028 for IL5 Alhydrogel vs rAceyCP1_R,
P = 0.015 for IL13 Alhydrogel vs rAceyCP1_R.
https://doi.org/10.1371/journal.pntd.0007345.g010
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S2 Table. Protein-coding gene predictions, annotations, and RNA-seq values for A. ceyla-
nicum genes. Included as Separate Excel Table. Data columns are as follows. Gene: a given
predicted protein-coding gene in the A. ceylanicum genome assembly [35]. All further data
columns are pertinent to that particular gene. Vaccine candidate: specific abbreviations used
in this text for genes encoding possible subunits of vaccines (e.g., AceyCP1 for the gene
Acey_s0154.g3007). Annotations. Most of these annotations are from our previous analyses
[35]. However, two sets of annotations have been updated and recomputed for this paper:
Pfam and InterPro. Coordinates: genomic coordinates in the A. ceylanicum genome assembly.
The strand orientation of the gene, with respect to the assembly sequence’s orientation, is
given as ’[+]’ (sense strand) or ’[–]’ (antisense strand). Max_prot_size: the size of the largest
predicted protein product. Start/stop codons: whether a predicted gene has both start and
stop codons (’Complete’), a start or stop codon only (’Start_codon’ or ’Stop_codon’), or is a
completely fragmentary prediction (blank in this field; there are 9 such genes, all of which
come from smaller genomic scaffolds). Prot_size: this shows the full range of sizes for all pro-
tein products from a gene’s predicted isoforms. Phobius: this denotes predictions of signal
and transmembrane sequences made with Phobius [68]. ’SigP’ indicates a predicted signal
sequence, and ’TM’ indicates one or more transmembrane-spanning helices, with N helices
indicated with ’(Nx)’. Varying predictions from different isoforms are listed. Psegs: this shows
what fraction of a protein is low-complexity sequence, as detected by pseg [69]. Both the pro-
portion of such sequence (ranging from 0.01 to 1.00) and the exact ratio of low-complexity res-
idues to total residues are given. Proteins with no predicted low-complexity residues are blank.
NCoils: this shows coiled-coil domains, predicted by ncoils [70]. As with Psegs, the relative
and absolute fractions of each protein’s coiled-coil residues are shown. Pfam: newly predicted
domains (in this study) from Pfam 31.0 [71], using hmmscan with reliably curated domain-
specific thresholds. InterPro: newly predicted domains (in this study) from InterPro [72],
using InterProScan 5.18–57.0 with default settings. GO_terms: Gene Ontology terms, gener-
ated with Blast2GO using default settings. Housekeeping: a set of 406 genes (with strict, 1-to-1
orthologies between the two species being compared) that we observed to be consistently
active both in A. ceylanicum and C. elegans under all RNA-seq conditions tested. These condi-
tions included a complete passage through infection for A. ceylanicum, and a complete life
cycle determined by modENCODE for C. elegans. ASP: 432 genes that we designated as being
classic ASP genes, as defined by their having at least one copy of a PFAM CAP domain
(PF00188.21) at E� 10−2, and by their not having already been defined as ASPR genes (this
second condition excluded only one gene). This definition successfully detected all previously
known ASPs in Ancylostoma, including the highly divergent ASP-7. ASPR: 92 genes that we
designated as a cryptic ASP-Related gene family, on the basis of strong similarities to one
another (as defined by a convergent psi-BLAST search with an E-value threshold of 10−9) and
by more distant similarities to ASP genes (detectable either with psi-BLAST or with interative
HMMER/jackhmmer searches). SL4P: 24 genes that we designated as a family of Strongylid
L4 Proteins, on the basis of strong similarities to one another (as defined by a convergent
psi-BLAST search with an E-value threshold of 10−6). SCVP: 53 genes that we designated as
a family of Secreted Clade V Proteins, on the basis of strong similarities to one another (as
defined by a convergent psi-BLAST search with an E-value threshold of 10−6). Other_secre-
ted_groups: the purpose of this category was to detect small, secreted, and conserved but
unfamiliar proteins that might be up- or down-regulated during infection. This general cate-
gory includes subcategories whose statistical overrepresentations during changes of gene
activity (between developmental stages or drug treatments) are listed in Supplementary
Table 10. The subcategories are: Secreted_100, Secreted_150, Secreted_200, Secreted_Any,
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Cons_Secreted_100, Cons_Secreted_150, Cons_Secreted_200, Cons_Secreted_Any, Hco_
Cons_Secreted_100, Hco_Cons_Secreted_150, Hco_Cons_Secreted_200, Hco_Cons_Secrete-
d_Any, Hco_Cons_Only_Secreted_100, Hco_Cons_Only_Secreted_150, Hco_Cons_Only_
Secreted_200, and Hco_Cons_Only_Secreted_Any. To be in any of these subcategories, a gene
had to have a full-length gene prediction (i.e., not be fragmentary). To be ’Secreted’, a gene had
to have at least one product predicted to be classically secreted by Phobius; to be ’Cons_Se-
creted’, it also had to belong to an OrthoMCL group from the 14-species OrthoMCL run; to be
’Hco_Cons_Secreted’, the OrthoMCL group had to include H. contortus; to be ’Hco_Con-
s_Only_Secreted’, the OrthoMCL group had to include only A. ceylanicum and H. contortus.
For products with maximum sizes of�100,�150, or�200 residues, these sizes are noted as
suffixes. Acey-specific_protease: a set of protease genes that we identified as being of particu-
lar interest as vaccine candidates due to their being upregulated during early infection, not
being significantly downregulated, not having mammalian orthologs, and having one or more
H. contortus homologs that were also upregulated during infection. Acey-specific_protea-
se_inhibitor: a single protease inhibitor gene selected as a possible vaccine candidate, by iden-
tical criteria to those used for proteases. Drug_target: a set of 80 genes whose products we
identified as being of particular interest as drug targets, based upon a visible phenotype in
C. elegans, a known homologous protein structure, presence in one or more other parasites,
absence from mammals, and a known small-molecular ligand (ideally, a drug). On manual
examination, we rejected 8 of these genes as being likely to be mispredictions (because BlastP
or psi-BLAST against NCBI-nr revealed them to have mammalian homologs) but accepted 72
others as being plausible drug targets. All 80 genes are annotated with their protein class and
any information about their feasibility as drug targets. RNA-seq expression values. All of these
have been computed for this paper as described in Methods. The data for adult male intestine
are from Mitreva and coworkers [38]; all other RNA-seq data are from our previous work [35].
By recomputing all of these data in a single pipeline, we generated expression values that could
be reasonably compared between the two publications. Acey_[stage].TPM, for the following
stages—male_intestine, L3i, 24.HCM, 24.PI, 5.D, 12.D, 17.D, 19.D, Alb.4hr.D18, noAlb.
cont.D18, 18D.Cry5B.4hr, 18D.HEPES.4hr, 18D.Cry5B.24hr, 18D.HEPES.24hr, 18D.SB.
plusCry5B, 18D.SB.plusHEPES: the gene expression levels detected in each of these stages,
in units of Transcripts Per Million (TPM), as computed by Salmon [40]. Acey_[stage].reads,
for the following stages—male_intestine, L3i, 24.HCM, 24.PI, 5.D, 12.D, 17.D, 19.D,
Alb.4hr.D18, noAlb.cont.D18, 18D.Cry5B.4hr, 18D.HEPES.4hr, 18D.Cry5B.24hr, 18D.
HEPES.24hr, 18D.SB.plusCry5B, 18D.SB.plusHEPES: the estimated number of reads
(rounded to the nearest integer) mapped to the genome for a given gene, as computed by
Salmon [40]. For both TPM and reads, the [stage] abbreviations signify the following stages.
male_intestine: dissected adult male intestines [38]. L3i: Infectious L3 larvae. 24.HCM: L3i
incubated for 24 hr in hookworm culture medium simulating infection. 24.PI: Larvae 24 hours
after infection (as L3i), in early stages of infection; majority of worms in stomach. 5.D: Larvae
5 days post infection (d.p.i.); sexual differentiation distinct, and majority of larvae in final L4;
worms in small intestine until adulthood. 12.D: Worms 12 d.p.i.; early adult stage, with few
gravid females and mature males. 17.D: Worms 17 d.p.i.; start of mature adult stage with onset
of egg-laying. 19.D: Worms 19 d.p.i.; mature adult stage. Alb.4hr.D18: Worms 18 d.p.i. treated
with albendazole for 4 hr. noAlb.cont.D18: Worms 18 d.p.i. treated with 0.2% DMSO buffer
rather than albendazole for 4 hr. 18D.Cry5B.4hr: Worms 18 d.p.i., then exposure to 100ug/mL
Cry5B for 4 hr. 18D.HEPES.4hr: Worms 18 d.p.i., then HEPES buffer control for 4hr. 18D.
Cry5B.24hr: Worms 18 d.p.i., then worms incubated in hookworm culture media for 24 hrs,
then exposed to 100ug/mL Cry5B for 4 hr. 18D.HEPES.24hr: Worms 18 d.p.i., then worms
incubated in hookworm culture media for 24 hrs, then exposed to HEPES buffer control for 4
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hr. 18D.SB.plusCry5B: Worms 18 d.p.i., then worms incubated in hookworm culture media
with 50uM SB203580 (p38 MAPK inhibitor) for 24 hrs, then exposed to 100 ug/mL Cry5B for 4
hr. 18D.SB.plusHEPES: Worms 18 d.p.i., then worms incubated in hookworm culture media
with 50uM SB203580 for 24 hr, then exposed to buffer control for 4 hr.
(XLSX)
S1 Fig. qRT-PCR primer efficiency tests for Syrian hamster cytokine primer sets on sple-
nocyte total RNA. Shown are threshold cycle (Ct) values regressed by Log10 serial dilutions.
Amplification factors and efficiencies were calculated using qPCR Efficiency Calculator
(Thermo Fisher).
(TIF)
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